Latest News for: cvh

Edit

BBIO-Acoramidis AG10-AHA 2025- ACM and CVH (early HF with and without AF) (BridgeBio Pharma Inc)

Public Technologies 08 Nov 2025
In the phase 3 ATTRibute-CM study,a acoramidis significantly reduced the risk of ACM or first CVH at Month 30 vs placebo, including in ... CVH ... ACM or first CVH through Month 30. First CVH through Month 30.
Edit

BBIO-Acoramidis AG10-AHA 2025- Variant ACM and First CVH (BridgeBio Pharma Inc)

Public Technologies 08 Nov 2025
In ATTRibute-CMa and its OLE,b acoramidis significantly improved ACM and first CVH in patients with ATTR-CM9-11 ... ACM/first CVH through Month 30 ... ACM/first CVH ACM only ... ACM/First CVH Through Month 30 ... Risk reduction of ACM/first CVH through Month 30.
Edit

BBIO-Acoramidis-AG10-HFSA-2025-Effect-on-CVM Recurrent-CVH-Cumulative-Incidence-Oral-Presentation (BridgeBio Pharma Inc)

Public Technologies 28 Sep 2025
In the phase 3 ATTRibute-CMa study, acoramidis treatment reduced the composite endpoint of ACM or first CVH vs placebo at Month 30, with evidence of an effect as early as Month 38,9 ... Risk of recurrent CVH.
Edit

BBIO-Acoramidis-AG10-HFSA-2025-OLE-ACM-and-CVH-by-Genotype (BridgeBio Pharma Inc)

Public Technologies 27 Sep 2025
was associated with consistently lower risks of ACM, ACM/first CVH, and first CVH compared with participants who delayed initiation in participants with both ATTRv-CM and ATTRwt-CM genotypes.
  • 1

Article Search

tools
×
×
×
×